10x Genomics Inc. (TXG) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
10x Genomics Inc. (TXG) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID warning (65/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (-143.8% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How TXG Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $642.8M | 69.1% | -9.5% | -$43.5M | $130.1M | -6.1% |
| FY 2024 | $610.8M | 67.9% | -31.9% | -$182.6M | -$5.7M | -33.4% |
| FY 2023 | $618.7M | 44% | -42.9% | -$255.1M | -$43.0M | -5.9% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring TXG)
- ✓Live walkthrough of TXG's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
TXG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TXG today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TXG. Explore sector supply chains on /butterfly.
TXG Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is 10x Genomics Inc. (TXG)?
In FY 2025 (10-K), TXG converted $642.8M of revenue into a 69.1% gross margin, 0% operating margin, and $130.1M in free cash flow (20.2% FCF margin).